Filgotinib

Drug Overview
Product Profiles
filgotinib: Rheumatoid arthritis (RA)
filgotinib: Ulcerative colitis
filgotinib: Crohn's disease

Figure 1: Filgotinib for rheumatoid arthritis – SWOT analysis
Figure 2: The authors drug assessment summary of filgotinib in rheumatoid arthritis
Figure 3: The authors drug assessment summary of filgotinib in rheumatoid arthritis
Figure 4: Filgotinib for ulcerative colitis – SWOT analysis
Figure 5: The authors drug assessment summary of filgotinib for ulcerative colitis
Figure 6: The authors drug assessment summary of filgotinib for ulcerative colitis
Figure 7: Filgotinib for Crohn’s disease – SWOT analysis
Figure 8: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 9: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 10: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25

Table 1: Filgotinib drug profile
Table 2: Filgotinib Phase III trials in rheumatoid arthritis
Table 3: Primary endpoint for filgotinib at week 12 in the Phase IIb DARWIN 2 trial
Table 4: Efficacy responses with filgotinib after 12 and 24 weeks of treatment in the DARWIN 1 trial (%)
Table 5: Filgotinib drug profile
Table 6: Filgotinib Phase III trials in ulcerative colitis
Table 7: Filgotinib drug profile
Table 8: Ongoing pivotal Phase III trials of filgotinib in Crohn’s disease
Table 9: Phase II trial data of filgotinib in Crohn’s disease
Table 10: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25